Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Dec. 3, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
波士頓--（商業新聞）--2024年12月3日--Tango Therapeutics, Inc.（納斯達克：TNGX）是一家臨牀階段的生物技術公司，致力於發現和提供下一代精準癌症藥物，今天宣佈，自2024年12月2日起，Tango Therapeutics的董事會補償委員會向一名新員工授予了非合格股票期權，購買187,500股普通股和31,250股限制性股票單位（RSUs），該授予根據Tango Therapeutics的2023年誘導計劃進行。
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
Tango Therapeutics 2023年誘導計劃專門用於向個人授予股權獎勵，以誘導這些個人進入Tango Therapeutics工作，符合納斯達克上市規則第5635(c)(4)條。
The options have an exercise price of $3.89 per share, which is equal to the closing price of Tango Therapeutics' common stock on December 2, 2024. Each option will vest as to 25% of the shares underlying such option on November 18, 2025 and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to such employee's continued employment on each vesting date. The RSU award will vest as to: (i) 10,416 shares on or about November 12, 2025, (ii) 10,417 shares on or about November 9, 2026, and (iii) 10,417 shares on or about November 8, 2027, subject to such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.
這些期權的行使價格爲每股3.89美元，等於Tango Therapeutics普通股在2024年12月2日的收盤價。每個期權將在2025年11月18日以該期權所對應的25%股權歸屬，並在此後每月以剩餘期權的1/36比例歸屬，在每個歸屬日期，均需遵循該員工繼續就業的條件。RSU獎勵將在以下時間歸屬：（i）2025年11月12日左右歸屬10,416股，（ii）2026年11月9日左右歸屬10,417股，以及（iii）2027年11月8日左右歸屬10,417股，均需遵循該員工繼續就業的條件。這些期權和RSUs受Tango Therapeutics 2023年誘導計劃的條款和條件的約束，該計劃於2023年2月獲批准，以及覆蓋授予的股票期權和RSU協議的條款和條件。
About Tango Therapeutics
關於Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit .
Tango Therapeutics是一家臨牀階段的生物技術公司，致力於發現新型藥物靶點並提供針對癌症治療的下一代精準醫學。Tango採用以患者爲中心的方法，利用合成致死的遺傳原理，發現和開發針對癌症中關鍵靶點的治療方案。這包括將精準腫瘤學靶點的範圍擴展到腫瘤抑制基因缺失等新領域，以及它們對癌細胞逃避免疫細胞殺滅能力的貢獻。有關更多信息，請訪問。
View source version on businesswire.com:
在businesswire.com查看源版本：
Investor:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
投資者：
薩姆·馬丁/安德魯·沃利斯
阿戈特夥伴
tango@argotpartners.com
Media:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
媒體：
阿曼達·布朗·加爾蓋
高級副總裁，通信，Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.
來源：Tango Therapeutics, Inc.
